Eli Lilly reports $24.4B in third-quarter revenue
Story updates
10:47:36 AM UTC
SquawkNews
By Patrick WingroveEli Lilly NYSE:LLY raised its full-year revenue forecast and beat third-quarter earnings expectations on Thursday, propelled by surging demand for injectable weight-loss drugs that could allay investor concerns about price erosion in US government health plans.The Indianapolis-ba…
10:48:57 AM UTC
SquawkNews
LILLY Q3 REV $24.40 BLN VS IBES ESTIMATE $22.61 BLN
10:53:41 AM UTC
SquawkNews
Eli Lilly reported Q3 2026 revenue of $24.4B, up 39% YoY, and non-GAAP EPS of $7.48 vs. $7.02 a year ago, driven by Mounjaro and Zepbound. The company raised full-year 2026 guidance.Material DetailsContext by AI AnalystThis is a late confirmation of a strong growth trend led by GLP-1s, with added t…
10:56:56 AM UTC
SquawkNews
Global pharmaceutical company Eli Lilly NYSE:LLYreported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 38.6% year on year to $24.4 billion. The company’s full-year revenue guidance of $91.5 billion at the midpoint came in 3.3% above analysts’ consensus estimates. Its n…
10:57:04 AM UTC
SquawkNews
Eli Lilly Q3 net income rises 16% to $6.45 billion; Q3 revenue climbs 39% to $24.4 billion Eli L
11:02:51 AM UTC
SquawkNews
更新版 1-更新 1-禮來因減肥藥銷售上調營收，因交易費用下調利潤 禮來上調全年營收預期至最高920億美元 減肥藥Mounjaro和Zepbound推動第三季度業績超預期 隨著禮來吸引新患者，對聯邦醫
11:09:53 AM UTC
SquawkNews
By Mackenzie TatananniEli Lilly cruised past Wall Street's third-quarter forecasts on Thursday as demand continued to surge for its blockbuster diabetes and obesity franchise.The world's largest pharmaceutical company reported adjusted earnings of $7.48 a share, while revenue climbed 39% to $24.4 b…
11:13:35 AM UTC
SquawkNews
Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, and non-GAAP diluted EPS of $7.48. Net income was $6.5 billion, while reported diluted EPS was $7.22. The company raised its 2026 revenue guidance to $91 billion to $92 billion and updated its full-year non-GAAP…